Solicitation of Nominations for Appointment to the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA), 20173-20174 [2023-07038]

Download as PDF Federal Register / Vol. 88, No. 65 / Wednesday, April 5, 2023 / Notices III. How To Use the Notice This notice lists the OCPM chapters and subjects published during the quarter covered by the notice so the reader may determine whether any are of particular interest. The OCPM can be accessed at https://www.hhs.gov/about/ agencies/omha/the-appeals-process/ case-processing-manual/. IV. OCPM Releases for October Through December 2022 The OCPM is used by OMHA adjudicators and staff to administer the OMHA program. It offers day-to-day operating instructions, policies, and procedures based on statutes and regulations, and OMHA directives. The following is a list and description of new OCPM provisions and the subject matter. This information is available on our website at https:// www.hhs.gov/about/agencies/omha/theappeals-process/case-processingmanual/. OCPM Chapter 12: Administrative Record and Exhibiting On October 28, 2022, OMHA issued OCPM Chapter 12, which provides guidance on processing and developing the administrative record for OMHA appeals. OMHA is responsible for creating and organizing a complete record of the evidence and administrative proceedings of the appealed matter. This new chapter explains how OMHA obtains the case file from the prior adjudicating entity, as well as how OMHA organizes and exhibits records, creates an index of the administrative record, and processes new evidence. The chapter also details how to document electronic and oral communications, ensure the record is complete, and address other recordrelated issues that could arise during the appeal process. Karen Ames, Executive Director of Operations, Office of Medicare Hearings and Appeals. [FR Doc. 2023–06995 Filed 4–4–23; 8:45 am] BILLING CODE 4150–46–P lotter on DSK11XQN23PROD with NOTICES1 DEPARTMENT OF HEALTH AND HUMAN SERVICES Request for Nominations to the Advisory Council on Alzheimer’s Research, Care, and Services Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services. ACTION: Notice. AGENCY: VerDate Sep<11>2014 17:44 Apr 04, 2023 The Secretary of HHS established the Advisory Council on Alzheimer’s Research, Care, and Services to provide advice and consultation to the Secretary on how to prevent or reduce the burden of Alzheimer’s disease and related dementias on people with the disease and their caregivers. The Secretary signed the charter establishing the Advisory Council on May 23, 2011. HHS is soliciting nominations for six (6) new non-federal members of the Advisory Council to replace the six (6) members whose terms will end September 30, 2023. Nominations should include, at a minimum, the nominee’s contact information (current mailing address, email address, and telephone number) and current curriculum vitae or resume. DATES: Submit nominations by email or USPS mail before COB on April 28, 2023. SUMMARY: Jkt 259001 Nominations should be sent by email to: Helen Lamont, Ph.D., HHS Office of the Assistant Secretary for Planning and Evaluation, Room 424E, Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201, helen.lamont@hhs.gov and napa@ hhs.gov. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Helen Lamont (202) 260–6075, helen.lamont@hhs.gov. SUPPLEMENTARY INFORMATION: The Advisory Council on Alzheimer’s Research, Care, and Services meets quarterly to discuss programs that impact people with Alzheimer’s disease and related dementias and their caregivers. The Advisory Council makes recommendations to Congress and the Secretary of Health and Human Services about ways to reduce the financial impact of Alzheimer’s disease and related dementias and to improve the health outcomes of people with these conditions. The Advisory Council also provides feedback on a National Plan to Address Alzheimer’s disease. On an annual basis, the Advisory Council evaluates the implementation of the recommendations through an updated National Plan. The National Alzheimer’s Project Act, Public Law 111–375 (42 U.S.C. 11225), requires that the Secretary of Health and Human Services (HHS) establish the Advisory Council on Alzheimer’s Research, Care, and Services. The Advisory Council is governed by provisions of Public Law 92–463 (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory committees. The Advisory Council consists of 22 members. Ten members are designees PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 20173 from Federal agencies including the Centers for Disease Control and Prevention, Administration for Community Living, Centers for Medicare & Medicaid Services, Indian Health Service, National Institutes of Health, National Science Foundation, Food and Drug Administration, Agency for Healthcare Research and Quality, Health Resources and Services Administration, and Department of Veterans Affairs. The Advisory Council also consists of 12 non-federal members selected by the Secretary who represent 6 categories of people impacted by dementia: dementia caregivers (2), health care providers (2), representatives of State or local health departments (2), researchers with dementia-related expertise in basic, translational, clinical, or drug development science (2), voluntary health association representatives (2), and dementia patient advocates (2), including one advocate who is currently living with dementia. At this time, the Secretary of HHS is seeking nominations for new members for each category (caregiver, health care provider, state representative, researcher, association representative, dementia patient advocate currently living with Alzheimer’s disease or a related dementia), to replace the members whose terms will end on September 30, 2023, for a total of six (6) new members to the Advisory Council. After receiving nominations, the Secretary, with input from his staff, will make the final decision, and the new members will be announced soon after. Members shall be invited to serve until the Advisory Council sunsets on December 31, 2025 or a 4-year term if the National Alzheimer’s Project Act is reauthorized. Members will serve as Special Government Employees. Dated: March 20, 2023. Miranda Lynch-Smith, Senior Official Performing the Duties of the Assistant Secretary for Planning and Evaluation. [FR Doc. 2023–07007 Filed 4–4–23; 8:45 am] BILLING CODE 4150–05–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Solicitation of Nominations for Appointment to the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) Office of the Assistant Secretary for Health, Office of the Secretary, U.S. Department of Health and Human Services. AGENCY: E:\FR\FM\05APN1.SGM 05APN1 20174 ACTION: Federal Register / Vol. 88, No. 65 / Wednesday, April 5, 2023 / Notices Notice. The Office of the Assistant Secretary for Health (OASH) is seeking nominations for membership on the Advisory Committee on Blood and Tissue Safety and Availability (referred to as ACBTSA and/or the Committee). This announcement is to solicit nominations of qualified candidates to five public member positions on the ACBTSA. The ACBTSA is a federal advisory committee within the U.S. Department of Health and Human Services (HHS). Qualified individuals will be nominated to the Secretary of Health and Human Services for consideration of appointment as members of the ACBTSA. Members are invited to serve on the Committee for up to four-year terms. The Committee was established to provide advice to the Secretary on a range of policy issues related to blood, blood products, and tissues. The functions of the Committee are solely advisory in nature. DATES: Nominations for membership on the ACBTSA must be received no later than 5:00 p.m. (ET), May 5, 2023. Packages received after this time will not be considered for the current membership cycle. ADDRESSES: All nominations should be electronically mailed in one email to ACBTSA@hhs.gov. Please include in the subject line of the email: ACBTSA Application. FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, Tower Building, 1101 Wootton Parkway, Rockville, MD 20852. Email: ACBTSA@hhs.gov. Phone: 202–795– 7608. Additional information about ACBTSA can be obtained by accessing the Committee’s website at https:// www.hhs.gov/oidp/advisory-committee/ blood-tissue-safety-availability/ index.html. SUPPLEMENTARY INFORMATION: ACBTSA is authorized under 42 U.S.C. 217a, section 222 of the Public Health Service (PHS) Act, as amended. The Committee is governed by the provisions of the Federal Advisory Committee Act (FACA), Public Law 92–463, as amended, which sets forth standards for the formation and use of advisory committees. The ACBTSA advises, assists, consults with, and makes policy recommendations to the Secretary, through the Assistant Secretary for Health, regarding broad responsibilities related to the safety of blood, blood products, tissues, and organs. For solid lotter on DSK11XQN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 17:44 Apr 04, 2023 Jkt 259001 organs and blood stem cells, the Committee’s work is limited to policy issues related to donor derived infectious disease complications of transplantation. The Advisory Committee consists of up to 29 members, including the voting and non-voting members and the Chair and Vice Chair or Co-Chairs. The Committee consists of not more than 23 voting members; 14 public members, including the Chair, and nine (9) individuals designated to serve as official representative members. The public members are selected from state and local organizations, patient advocacy groups, provider organizations, academic researchers, ethicists, physicians, surgeons, scientists, risk communication experts, consumer advocates, and from among communities of persons who are frequent recipients of blood or blood products or who have received tissues or organs. The nine individuals who are appointed as official representatives are selected to serve the interests of the blood, blood products, tissue and organ professional organizations or business sectors. The representative members are selected from the following groups: The AABB (formerly the American Association of Blood Banks); American Association of Tissue Banks; Eye Bank Association of America; Association of Organ Procurement Organizations; and one of either the American Red Cross or America’s Blood Centers. The Committee composition can include additional representation from either the plasma protein fraction community or a trade organization; a manufacturer of blood, plasma, or other tissue/organ test kits; a manufacturer of blood, plasma or other tissue/organ equipment; a major hospital organization; or a major hospital accreditation organization. All voting members are appointed by the Secretary or designee. Public voting members are classified as special government employees (SGEs) and are subject to government ethics rules. Pursuant to an advance written agreement, SGE voting members shall receive no stipend from the federal government for the services they perform during their tenure on the Committee. However, the SGE voting members are entitled to receive per diem and reimbursement for travel expenses incurred for attending meetings of the Advisory Committee. Nominations Nominations are being sought for individuals who have expertise and qualifications necessary to contribute to the accomplishment of the ACBTSA’s objectives. The U.S. Department of PO 00000 Frm 00057 Fmt 4703 Sfmt 9990 Health and Human Services policy stipulates that committee membership be balanced in terms of points of view represented and the committee’s function. Appointments shall be made without discrimination on the basis of age, race, ethnicity, sexual orientation, gender identity, disability, veteran status, and cultural or religious status. In order to help ensure diverse groups and points of view are represented on the committee, nominees may provide this information when applying. Nominees must be U.S. citizens and cannot be full-time employees of the U.S. Government. Public members of the Committee are Special Government Employees (SGEs), requiring the filing of financial disclosure reports at the beginning and annually during their terms. Individuals who are selected for appointment will be required to provide detailed information regarding their financial interests and must receive annual ethics training. Candidates should submit the following items to be considered of appointment: • Current curriculum vitae or resume, including complete contact information (telephone numbers, mailing address, email address). • A letter of interest or personal statement from the nominee stating how their expertise would inform the work of ACBTSA (300 words or fewer). • Nominees are invited to identify any or some of the following: race, ethnicity, sexual orientation, gender identity, disability, veteran status and cultural or religious status. This is not mandatory for a complete application. Individuals can nominate themselves for consideration of appointment to the Committee. All nominations must include the required information in one email sent to ACBTSA@hhs.gov with the subject line, ‘‘ACBTSA Application.’’ Incomplete nomination applications will not be processed for consideration. Dated: March 13, 2023. James J. Berger, Senior Advisor for Blood and Tissue Policy, Designated Federal Officer, Advisory Committee on Blood and Tissue Safety and Availability, Office of the Assistant Secretary for Health, Department of Health and Human Services. [FR Doc. 2023–07038 Filed 4–4–23; 8:45 am] BILLING CODE 4150–41–P E:\FR\FM\05APN1.SGM 05APN1

Agencies

[Federal Register Volume 88, Number 65 (Wednesday, April 5, 2023)]
[Notices]
[Pages 20173-20174]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-07038]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Solicitation of Nominations for Appointment to the Advisory 
Committee on Blood and Tissue Safety and Availability (ACBTSA)

AGENCY: Office of the Assistant Secretary for Health, Office of the 
Secretary, U.S. Department of Health and Human Services.

[[Page 20174]]


ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Office of the Assistant Secretary for Health (OASH) is 
seeking nominations for membership on the Advisory Committee on Blood 
and Tissue Safety and Availability (referred to as ACBTSA and/or the 
Committee). This announcement is to solicit nominations of qualified 
candidates to five public member positions on the ACBTSA. The ACBTSA is 
a federal advisory committee within the U.S. Department of Health and 
Human Services (HHS). Qualified individuals will be nominated to the 
Secretary of Health and Human Services for consideration of appointment 
as members of the ACBTSA. Members are invited to serve on the Committee 
for up to four-year terms. The Committee was established to provide 
advice to the Secretary on a range of policy issues related to blood, 
blood products, and tissues. The functions of the Committee are solely 
advisory in nature.

DATES: Nominations for membership on the ACBTSA must be received no 
later than 5:00 p.m. (ET), May 5, 2023. Packages received after this 
time will not be considered for the current membership cycle.

ADDRESSES: All nominations should be electronically mailed in one email 
to [email protected]. Please include in the subject line of the email: 
ACBTSA Application.

FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal 
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS 
Policy, Office of the Assistant Secretary for Health, Department of 
Health and Human Services, Tower Building, 1101 Wootton Parkway, 
Rockville, MD 20852. Email: [email protected]. Phone: 202-795-7608. 
Additional information about ACBTSA can be obtained by accessing the 
Committee's website at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/.

SUPPLEMENTARY INFORMATION: ACBTSA is authorized under 42 U.S.C. 217a, 
section 222 of the Public Health Service (PHS) Act, as amended. The 
Committee is governed by the provisions of the Federal Advisory 
Committee Act (FACA), Public Law 92-463, as amended, which sets forth 
standards for the formation and use of advisory committees. The ACBTSA 
advises, assists, consults with, and makes policy recommendations to 
the Secretary, through the Assistant Secretary for Health, regarding 
broad responsibilities related to the safety of blood, blood products, 
tissues, and organs. For solid organs and blood stem cells, the 
Committee's work is limited to policy issues related to donor derived 
infectious disease complications of transplantation.
    The Advisory Committee consists of up to 29 members, including the 
voting and non-voting members and the Chair and Vice Chair or Co-
Chairs. The Committee consists of not more than 23 voting members; 14 
public members, including the Chair, and nine (9) individuals 
designated to serve as official representative members. The public 
members are selected from state and local organizations, patient 
advocacy groups, provider organizations, academic researchers, 
ethicists, physicians, surgeons, scientists, risk communication 
experts, consumer advocates, and from among communities of persons who 
are frequent recipients of blood or blood products or who have received 
tissues or organs. The nine individuals who are appointed as official 
representatives are selected to serve the interests of the blood, blood 
products, tissue and organ professional organizations or business 
sectors. The representative members are selected from the following 
groups: The AABB (formerly the American Association of Blood Banks); 
American Association of Tissue Banks; Eye Bank Association of America; 
Association of Organ Procurement Organizations; and one of either the 
American Red Cross or America's Blood Centers. The Committee 
composition can include additional representation from either the 
plasma protein fraction community or a trade organization; a 
manufacturer of blood, plasma, or other tissue/organ test kits; a 
manufacturer of blood, plasma or other tissue/organ equipment; a major 
hospital organization; or a major hospital accreditation organization.
    All voting members are appointed by the Secretary or designee. 
Public voting members are classified as special government employees 
(SGEs) and are subject to government ethics rules. Pursuant to an 
advance written agreement, SGE voting members shall receive no stipend 
from the federal government for the services they perform during their 
tenure on the Committee. However, the SGE voting members are entitled 
to receive per diem and reimbursement for travel expenses incurred for 
attending meetings of the Advisory Committee.

Nominations

    Nominations are being sought for individuals who have expertise and 
qualifications necessary to contribute to the accomplishment of the 
ACBTSA's objectives. The U.S. Department of Health and Human Services 
policy stipulates that committee membership be balanced in terms of 
points of view represented and the committee's function. Appointments 
shall be made without discrimination on the basis of age, race, 
ethnicity, sexual orientation, gender identity, disability, veteran 
status, and cultural or religious status. In order to help ensure 
diverse groups and points of view are represented on the committee, 
nominees may provide this information when applying. Nominees must be 
U.S. citizens and cannot be full-time employees of the U.S. Government. 
Public members of the Committee are Special Government Employees 
(SGEs), requiring the filing of financial disclosure reports at the 
beginning and annually during their terms. Individuals who are selected 
for appointment will be required to provide detailed information 
regarding their financial interests and must receive annual ethics 
training. Candidates should submit the following items to be considered 
of appointment:
     Current curriculum vitae or resume, including complete 
contact information (telephone numbers, mailing address, email 
address).
     A letter of interest or personal statement from the 
nominee stating how their expertise would inform the work of ACBTSA 
(300 words or fewer).
     Nominees are invited to identify any or some of the 
following: race, ethnicity, sexual orientation, gender identity, 
disability, veteran status and cultural or religious status. This is 
not mandatory for a complete application.
    Individuals can nominate themselves for consideration of 
appointment to the Committee. All nominations must include the required 
information in one email sent to [email protected] with the subject line, 
``ACBTSA Application.'' Incomplete nomination applications will not be 
processed for consideration.

    Dated: March 13, 2023.
James J. Berger,
Senior Advisor for Blood and Tissue Policy, Designated Federal Officer, 
Advisory Committee on Blood and Tissue Safety and Availability, Office 
of the Assistant Secretary for Health, Department of Health and Human 
Services.
[FR Doc. 2023-07038 Filed 4-4-23; 8:45 am]
BILLING CODE 4150-41-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.